Stem Cell Therapy in China
Why Choose China for Stem Cell Therapy?
China has become one of the leading destinations for patients seeking stem cell therapies, particularly for conditions where European healthcare offers limited options. It is important to distinguish between approved, evidence-based applications and experimental treatments — and to choose facilities operating within China's regulatory framework.
What's Included
- Approved applications for haematological conditions (bone marrow transplants)
- Clinical trial access at research hospitals
- Mesenchymal stem cell therapies for joint conditions
- Rigorous regulatory compliance screening by coordinator
- Full transparency on regulatory status of each treatment
Cost Comparison
| Location | Typical Cost |
|---|---|
| China (Grade 3A Hospital) | €8,000 – €30,000 |
| Europe (Private) | Rarely available or approved |
Costs are indicative ranges and vary by hospital, procedure complexity, and individual case. Exact quotes provided after medical record review.
How does the process work?
From initial assessment to returning home — we guide every step.
See the full patient journey →Frequently Asked Questions
What stem cell treatments are legitimately available?
Haematopoietic stem cell transplantation (bone marrow transplant) for blood cancers is well-established worldwide including China. Mesenchymal stem cell therapies for degenerative conditions are in clinical trials at major research hospitals. We only refer to facilities and programmes operating within China's NMPA regulatory framework.
How do I avoid illegitimate stem cell clinics?
Key red flags: clinics that promise cures for any condition, no published trial data, no regulatory approval details, payment upfront only. We pre-screen all partners for regulatory compliance and will not refer to unverified facilities.
What conditions might benefit from stem cell therapy?
Conditions with evidence or active trial programmes include haematological cancers (AML, ALL, lymphoma), multiple sclerosis (within trials), ALS/MND (trial phase), Parkinson's (early trials), and degenerative joint conditions.